Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors

Xu, YY; Wang, YK; Gong, JF; Zhang, XT; Peng, Z; Sheng, XA; Mao, CY; Fan, QX; Bai, YX; Ba, Y; Jiang, D; Yang, F; Qi, CS; Li, J; Wang, XC; Zhou, J; Lu, M; Cao, YS; Yuan, JJ; Liu, D; Wang, ZH; Fang, JM; Shen, L

Shen, L (corresponding author), Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Fu Cheng Rd 52, Beijing 100142, Peoples R China.

GASTRIC CANCER, 2021; 24 (4): 913

Abstract

Purpose RC48 contains the novel humanized anti-HER2 antibody hertuzumab conjugated to MMAE via a cleavable linker. A phase I study was initiated to ev......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索